CSI Market
Sign In | Register

Celyad Oncology Sa (CYAD) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access CYAD Annual Balance Sheets →
Changes in quarterly balance sheet trends offer perspective on how Celyad Oncology Sa balances growth, leverage, and shareholder equity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2023)
(Dec 31 2022) 0 0 0
Assets
Cash And Cash Equivalents5.43
Cash & Short-term Investments5.00
Accounts receivable0.70
Trade & Other Current Receivables (IFRS combined total)0.96
Other Noncurrent Assets0.23
Assets Held For Sale Current0.00
Other Current Assets2.04
Total Current Assets8.40
Equipment/Property/Plant Net0.93
Intangible AssetsAnd Goodwill0.70
Total Assets13.30
Liabilities
Other Liabilities, Current6.65
Total Current Liabilities6.65
Long-term debt0.00
Total Long-term Debt0.00
Other liabilities, Noncurrent5.53
Total Liabilities12.19
Stockholders' Equity
Other Equity0.00
Common Stockholder's Equity1.11
Total Stockholder's Equity1.11
Liabilities & Stockholder's Equity13.30
4 historic quarters locked

Sign in to unlock the full Celyad Oncology Sa balance sheet history.

Sign In Create Free Account

About Celyad Oncology Sa Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-23-078009

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.